UNSPSC 51314309: Chlorpheniramine/dextromethorphan/glycerol, iodinated

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314309 Chlorpheniramine/dextromethorphan/glycerol, iodinated is a Commodity code that shows limited recent state and local procurement activity aligned with its nominal scope. The source records three recent opportunities, but only one—a Seminole County, Florida IFB for naloxone and drug deactivation systems—involves pharmaceutical procurement, and that opportunity targets naloxone rather than the chlorpheniramine-based formulation the code names. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products and the Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions both address pharmaceutical supply at scale but do not cite specific active pharmaceutical ingredients or narrow product lines. State and local health departments, cooperative purchasing alliances, and county community health programs appear to be the issuing bodies using this code, though the recent record is sparse and does not establish a pattern of repeat buyers under this specific code.

The geographic spread is limited to Florida, Minnesota, Oregon (through MMCAP participation), and Texas in the recent record. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; vendors were required to submit electronic bids with all shipping and delivery costs included, and the contract carried a two-year initial term with a one-year renewal option. The MMCAP RFP (S1070000015802, due March 26, 2026) sought manufacturers to supply generic pharmaceuticals and OTC products through authorized wholesalers with contracts effective July 1, 2026, structured around price competitiveness (75 percent of evaluation weight) and administrative compliance; incumbents' amendments would run through June 30, 2028. Neither opportunity shows an explicit set-aside designation. The code shows no robust recent activity pattern and warrants a watch-only posture until issuing-body solicitation frequency increases.